JPX · 4570.T
Immuno-Biological Laboratories Co., Ltd.
¥1,027-¥12 (-1.15%)
Immuno-Biological Laboratories Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.12% below the high.
Loading market information…
JPX · 4591.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Ribomic Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ribomic Inc.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ribomic Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥1,027-¥12 (-1.15%)
Immuno-Biological Laboratories Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.12% below the high.
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
¥132+¥2 (+1.54%)
PRISM BioLab Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
¥559¥0 (0.0%)
Kringle Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.56% below the high.
¥215+¥1 (+0.47%)
Trans Genic Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
¥59-¥2 (-3.28%)
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
¥142+¥2 (+1.43%)
Perseus Proteomics Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.24% below the high.
